- Home
- AGEN vs ISRL Comparison
AGEN vs ISRL Comparison
Compare AGEN & ISRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- ISRL
- Stock Information
- Founded
- AGEN 1994
- ISRL 2021
- Country
- AGEN United States
- ISRL United States
- Employees
- AGEN N/A
- ISRL N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ISRL Blank Checks
- Sector
- AGEN Health Care
- ISRL Finance
- Exchange
- AGEN Nasdaq
- ISRL Nasdaq
- Market Cap
- AGEN 87.7M
- ISRL 79.7M
- IPO Year
- AGEN 2000
- ISRL 2023
- Fundamental
- Price
- AGEN $4.28
- ISRL $12.50
- Analyst Decision
- AGEN Buy
- ISRL
- Analyst Count
- AGEN 2
- ISRL 0
- Target Price
- AGEN $14.50
- ISRL N/A
- AVG Volume (30 Days)
- AGEN 497.3K
- ISRL 2.7K
- Earning Date
- AGEN 08-11-2025
- ISRL 01-01-0001
- Dividend Yield
- AGEN N/A
- ISRL N/A
- EPS Growth
- AGEN N/A
- ISRL N/A
- EPS
- AGEN N/A
- ISRL 0.14
- Revenue
- AGEN $101,706,000.00
- ISRL N/A
- Revenue This Year
- AGEN $26.25
- ISRL N/A
- Revenue Next Year
- AGEN N/A
- ISRL N/A
- P/E Ratio
- AGEN N/A
- ISRL $93.40
- Revenue Growth
- AGEN N/A
- ISRL N/A
- 52 Week Low
- AGEN $1.38
- ISRL $11.13
- 52 Week High
- AGEN $7.34
- ISRL $14.00
- Technical
- Relative Strength Index (RSI)
- AGEN 38.46
- ISRL 51.82
- Support Level
- AGEN $4.31
- ISRL $12.40
- Resistance Level
- AGEN $4.70
- ISRL $12.80
- Average True Range (ATR)
- AGEN 0.26
- ISRL 0.22
- MACD
- AGEN -0.01
- ISRL 0.01
- Stochastic Oscillator
- AGEN 17.86
- ISRL 68.91
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.